No Data
No Data
Jacobio Pharmaceuticals Doses 1st Patient in Phase 3 Trial of Lung Cancer Drug
The first patient was administered in the registration-based Phase III clinical study of JAB-3312 in combination with Glecirasib by Gakuso-B (01167).
Jiakosi-B (01167) announced that the company's self-developed SHP2 inhibitor JAB-3312 and...
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
After the PD-1 era, the heavy-duty variety IND was accepted, and GSK (01167) is moving towards the fast lane.
According to the app Zhītōng Cáijīng, on July 10th, the National Medical Products Administration's Center for Drug Evaluation website showed that Jasco's (01167) broad-spectrum KRAS inhibitor, JAB-23E73 (previously named JAB-23400, JAB-23425), has had its New Drug Application (IND) for clinical trials accepted. This product is currently the global leader in oral broad-spectrum KRAS inhibitors. KRAS is a popular target pursued by domestic and foreign companies. There are 2.7 million new patients with KRAS mutations worldwide each year. As...
Jaccs-B (01167.HK) repurchased 163,500 shares for HKD 250,000 on June 27th.
Jiakesi-B (01167.HK) announced on June 27 that it spent HKD 250,000 to repurchase 163,500 shares.
On June 26, Jaks-B (01167.HK) spent HKD 223,000 to repurchase 139,500 shares.
On June 26th, JAKOS-B (01167.HK) announced the purchase of 139,500 shares for HKD 223,000.
No Data